This document presents information about echolocation in animals. It begins with an introduction to echolocation and mentions that bats, dolphins, and whales use this ability to navigate with sound. It then provides details on how echolocation works, such as bats emitting clicks and interpreting the echoes to locate objects. The document also discusses how animals like moths have evolved defenses against echolocating predators. Finally, it notes how technology has been inspired by echolocation abilities in nature, with examples including sonar, radar, and assistive devices for blind humans.
This oncology-focused immunotherapy company is developing first-in-class, targeted immunotherapies for cancer prevention. Their lead product NeuVax targets HER2-positive breast cancer in ongoing phase 3 trials. If successful, NeuVax could redefine standard of care for the majority of breast cancer patients who have low or intermediate HER2 expression. The company is also developing GALE-301, a vaccine targeting Folate Binding Protein for ovarian and endometrial cancers, which has shown preliminary efficacy in reducing recurrence rates in phase 1/2a trials.
The document summarizes immunotherapy approaches for treating cancer patients, including therapeutic vaccines, passive immunotherapy using monoclonal antibodies, and adoptive cell transfer therapy. It discusses antigens targeted by vaccines, types of vaccines like whole cell, peptide, and dendritic cell vaccines, and adjuvants used to stimulate immune responses. It also notes challenges faced by immunotherapy like tumor evasion mechanisms and the need for clinical efficacy data.
This document discusses various aspects of immunotherapy for allergies. It provides background on immunotherapy and describes different types, including subcutaneous, sublingual, oral, inhalation, and nasal immunotherapy. It discusses tests used for allergic patients like skin prick tests and RAST. It covers determining maintenance doses, benefits of immunotherapy, potential adverse reactions, and elements of informed consent. It also describes accelerated schedules like cluster and rush immunotherapy and their risks compared to standard schedules.
Robert L. Ferris, MD, PhD, FACS discusses head and neck cancer in this CME activity titled Evaluating Immunotherapy as a New Pillar of Multimodal Head and Neck Cancer Care: Where Does Checkpoint Blockade Fit?. For the full presentation, downloadable practice aids, transcript, complete CME information, and to apply for credit please visit us at http://bit.ly/2eaLosT. CME credit will be available until October 24, 2017.
This document provides an overview of immunotherapy for cancer. It discusses how immunotherapy works by boosting the body's natural immune response against cancer cells. The main types of immunotherapy discussed are monoclonal antibodies, cancer vaccines, and non-specific immunotherapies like cytokines and interferons. Monoclonal antibodies are engineered antibodies that target specific antigens on cancer cells, while cancer vaccines are designed to trigger an immune response against tumor antigens. Together, these immunotherapies help the immune system better recognize and destroy cancer cells.
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Will Roettger
This is a short briefing on the oncology immunotherapy PD-1/PD-L1 targeted agents currently under development. In this briefing we look at the competitive landscape, PD-1/PD-L1 product profiles, positioning, strategy, as well as a development timeline and SWOT on the BMS PD-1 blocker nivolumab. Updates to this briefing will come as newer information is discovered.
n overview of current immunotherapy therapies used to treat cancer. Also provides MOA of various medications, and updates on SITC guidelines for metastatice melanoma.
This document presents information about echolocation in animals. It begins with an introduction to echolocation and mentions that bats, dolphins, and whales use this ability to navigate with sound. It then provides details on how echolocation works, such as bats emitting clicks and interpreting the echoes to locate objects. The document also discusses how animals like moths have evolved defenses against echolocating predators. Finally, it notes how technology has been inspired by echolocation abilities in nature, with examples including sonar, radar, and assistive devices for blind humans.
This oncology-focused immunotherapy company is developing first-in-class, targeted immunotherapies for cancer prevention. Their lead product NeuVax targets HER2-positive breast cancer in ongoing phase 3 trials. If successful, NeuVax could redefine standard of care for the majority of breast cancer patients who have low or intermediate HER2 expression. The company is also developing GALE-301, a vaccine targeting Folate Binding Protein for ovarian and endometrial cancers, which has shown preliminary efficacy in reducing recurrence rates in phase 1/2a trials.
The document summarizes immunotherapy approaches for treating cancer patients, including therapeutic vaccines, passive immunotherapy using monoclonal antibodies, and adoptive cell transfer therapy. It discusses antigens targeted by vaccines, types of vaccines like whole cell, peptide, and dendritic cell vaccines, and adjuvants used to stimulate immune responses. It also notes challenges faced by immunotherapy like tumor evasion mechanisms and the need for clinical efficacy data.
This document discusses various aspects of immunotherapy for allergies. It provides background on immunotherapy and describes different types, including subcutaneous, sublingual, oral, inhalation, and nasal immunotherapy. It discusses tests used for allergic patients like skin prick tests and RAST. It covers determining maintenance doses, benefits of immunotherapy, potential adverse reactions, and elements of informed consent. It also describes accelerated schedules like cluster and rush immunotherapy and their risks compared to standard schedules.
Robert L. Ferris, MD, PhD, FACS discusses head and neck cancer in this CME activity titled Evaluating Immunotherapy as a New Pillar of Multimodal Head and Neck Cancer Care: Where Does Checkpoint Blockade Fit?. For the full presentation, downloadable practice aids, transcript, complete CME information, and to apply for credit please visit us at http://bit.ly/2eaLosT. CME credit will be available until October 24, 2017.
This document provides an overview of immunotherapy for cancer. It discusses how immunotherapy works by boosting the body's natural immune response against cancer cells. The main types of immunotherapy discussed are monoclonal antibodies, cancer vaccines, and non-specific immunotherapies like cytokines and interferons. Monoclonal antibodies are engineered antibodies that target specific antigens on cancer cells, while cancer vaccines are designed to trigger an immune response against tumor antigens. Together, these immunotherapies help the immune system better recognize and destroy cancer cells.
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Will Roettger
This is a short briefing on the oncology immunotherapy PD-1/PD-L1 targeted agents currently under development. In this briefing we look at the competitive landscape, PD-1/PD-L1 product profiles, positioning, strategy, as well as a development timeline and SWOT on the BMS PD-1 blocker nivolumab. Updates to this briefing will come as newer information is discovered.
n overview of current immunotherapy therapies used to treat cancer. Also provides MOA of various medications, and updates on SITC guidelines for metastatice melanoma.
This document discusses cancer immunotherapy. It begins by describing tumor antigens that can be recognized by the immune system, such as tumor-specific antigens, tumor-associated antigens, and antigens from oncogenic viruses. It then discusses how tumors evade the immune system and various approaches to immunotherapy, including active immunotherapies using vaccines made of tumor cells, purified antigens, or antigen-loaded dendritic cells. Passive immunotherapies discussed include adoptive cellular therapy, monoclonal antibodies, and immunotoxins. Clinical trials and effectiveness of different immunotherapies are also summarized.
The document discusses various approaches to immunotherapy in cancers, including targeted therapies, biologic therapies, angiogenesis inhibitors, and immune-based therapies. It describes cellular processes like the cell cycle and cell kinetics that are relevant for cancer growth. It provides details on specific targeted therapies for pathways like EGFR, HER2/neu, VEGF, and PI3K/Akt/mTOR that are dysregulated in cancers. Immunotherapies like HPV vaccines have been successful in preventing cervical cancers associated with HPV infection. Overall, the document outlines current understandings and therapeutic approaches regarding tumor proliferation and immunotherapies for cancer.
A detailed ppt about cancer immunotherapy.
includes:-
Immunosurveillance and Immunoediting
Dentritic cell vaccines
Antibody therapy
Combined therapy
immune blockades
Cytokine therapy
T cell therapy
Include latest research finding about therapy.
Cancer immunotherapy uses the immune system to fight cancer. It stimulates the patient's immune system to attack and reject tumor cells. William Coley first observed in the late 1800s that some cancer patients who got infections after surgery saw their cancer improve. This led him to try treating patients by infecting them with bacteria, known as Coley toxins. Modern immunotherapy includes monoclonal antibody therapies like rituximab that target specific proteins on cancer cells, cancer vaccines, and cytokines to boost the immune system. Researchers are also exploring newer monoclonal antibodies and using cloned immune cells from patients to treat their cancer.
Immunotherapy is a type of cancer treatment that uses components of the immune system to fight cancer. There are several types of immunotherapy including passive immunotherapy using monoclonal antibodies that target tumor antigens, active immunotherapies using cytokines, cancer vaccines, and cell-based therapies. Monoclonal antibodies can directly kill cancer cells, block proteins that help cancer grow, or be linked to chemotherapy drugs. Cancer vaccines work by boosting the immune system against tumor antigens. Adoptive immunotherapy transfers modified immune cells to the body to attack cancer. Immunotherapy has shown success in treating various cancer types and continues to be improved and developed further.
פרופ' סבר-הקורונה-אירוע מוסרי- האדם המוסרי april2020Zvi Sever
During the Corona event the old population's protection is an evidence that we are Moral Humans, Homo moralis
התנהגותו המוסרית המיוחדת של האדם במגפת הקורונה ב 2019, במהלכה כל האנושות נכנסה לבידוד על מנת שהזקנים לא יפגעו, מזכה את האדם בזכות להיקרא מעתה- האדם המוסרי
This document discusses cancer immunotherapy. It begins by describing tumor antigens that can be recognized by the immune system, such as tumor-specific antigens, tumor-associated antigens, and antigens from oncogenic viruses. It then discusses how tumors evade the immune system and various approaches to immunotherapy, including active immunotherapies using vaccines made of tumor cells, purified antigens, or antigen-loaded dendritic cells. Passive immunotherapies discussed include adoptive cellular therapy, monoclonal antibodies, and immunotoxins. Clinical trials and effectiveness of different immunotherapies are also summarized.
The document discusses various approaches to immunotherapy in cancers, including targeted therapies, biologic therapies, angiogenesis inhibitors, and immune-based therapies. It describes cellular processes like the cell cycle and cell kinetics that are relevant for cancer growth. It provides details on specific targeted therapies for pathways like EGFR, HER2/neu, VEGF, and PI3K/Akt/mTOR that are dysregulated in cancers. Immunotherapies like HPV vaccines have been successful in preventing cervical cancers associated with HPV infection. Overall, the document outlines current understandings and therapeutic approaches regarding tumor proliferation and immunotherapies for cancer.
A detailed ppt about cancer immunotherapy.
includes:-
Immunosurveillance and Immunoediting
Dentritic cell vaccines
Antibody therapy
Combined therapy
immune blockades
Cytokine therapy
T cell therapy
Include latest research finding about therapy.
Cancer immunotherapy uses the immune system to fight cancer. It stimulates the patient's immune system to attack and reject tumor cells. William Coley first observed in the late 1800s that some cancer patients who got infections after surgery saw their cancer improve. This led him to try treating patients by infecting them with bacteria, known as Coley toxins. Modern immunotherapy includes monoclonal antibody therapies like rituximab that target specific proteins on cancer cells, cancer vaccines, and cytokines to boost the immune system. Researchers are also exploring newer monoclonal antibodies and using cloned immune cells from patients to treat their cancer.
Immunotherapy is a type of cancer treatment that uses components of the immune system to fight cancer. There are several types of immunotherapy including passive immunotherapy using monoclonal antibodies that target tumor antigens, active immunotherapies using cytokines, cancer vaccines, and cell-based therapies. Monoclonal antibodies can directly kill cancer cells, block proteins that help cancer grow, or be linked to chemotherapy drugs. Cancer vaccines work by boosting the immune system against tumor antigens. Adoptive immunotherapy transfers modified immune cells to the body to attack cancer. Immunotherapy has shown success in treating various cancer types and continues to be improved and developed further.
פרופ' סבר-הקורונה-אירוע מוסרי- האדם המוסרי april2020Zvi Sever
During the Corona event the old population's protection is an evidence that we are Moral Humans, Homo moralis
התנהגותו המוסרית המיוחדת של האדם במגפת הקורונה ב 2019, במהלכה כל האנושות נכנסה לבידוד על מנת שהזקנים לא יפגעו, מזכה את האדם בזכות להיקרא מעתה- האדם המוסרי
9. She ridiculed the suggestion of Ernst Mayer, Richard Dawkins and other
ultra-Darwinians that evolutionary biology might be nearing completion
in terms of not requiring any major additions or revisions
“They’re finished,” Margulis declared “but that’s just a small blip in the 20th
century history of biology rather than a full-fledged and valid science.”
She emphasized that she had no
problem with the basic premise
of Darwinism. “Evolution no doubts
occur,occurs and it’s been seen to
and it’s occurring now.
Everyone who’s scientific-minded agrees es
The question is how does it occur?
Through symbiosis, one organism can
genetically absorb or infiltrate another
and thereby become more fit.
“We have this British-French business. Darwin’s all right and Lamarck is bad. It’s really terrible.”
http://blogs.scientificamerican.com/cross-check/2011/11/24/r-i-p-lynn-margulis-biological-rebel/